Aumolertinib: all 48 studies that test it

Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCNot yet recruitingNCT07873086Not applicable
• An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingNCT07863167Phase 2
• A Study of Aumolertinib in European Participants With Non-Small Cell Lung CancerRecruitingNCT07130916Phase 1
• A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCRecruitingNCT06951464Phase 2
• A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT06947811Phase 1/2
• Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingNCT06752408Phase 2
• Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNot yet recruitingNCT06463171Phase 2
• A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNot yet recruitingNCT06110663Phase 3
• Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceRecruitingNCT06043973Phase 3
• Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung CancerNot yet recruitingNCT05994339Phase 2/3
• Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.RecruitingNCT05946460Phase 2
• Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationNot yet recruitingNCT05778149Phase 2
• Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic HepatopathyRecruitingNCT05662813Phase 2
• A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingNCT04951635Phase 3
• Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade PatternsRecruitingNCT04922138Phase 2
• Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Phase 3
• Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung CancerNot yet recruitingNCT04755738Phase 2
• Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingNCT04455594Phase 2
• PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
• A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsStatus unknownNCT03849768Phase 3Results posted
• A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLCStatus unknownNCT02981108Phase 1/2Results posted
• A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCActive, not recruitingNCT07183189Phase 3
• Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLCActive, not recruitingNCT06300424Phase 2
• Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).WithdrawnNCT06227897Phase 2
• Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance StatusStatus unknownNCT05826483Phase 1
• An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143CompletedNCT05199610Phase 1
• To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic PopulationsCompletedNCT04969965Phase 1
• Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLCStatus unknownNCT04952168Phase 2
• A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR MutationStatus unknownNCT04951648Phase 3
• Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisStatus unknownNCT04944069Not applicable
• Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsActive, not recruitingNCT04923906Phase 3
• Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLCStatus unknownNCT04905550Phase 2
• Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib TreatmentStatus unknownNCT04882345Phase 2
• Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesStatus unknownNCT04870190Phase 3
• MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)Active, not recruitingNCT04841811Phase 3
• Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain MetastasesActive, not recruitingNCT04808752Phase 2
• Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFRStatus unknownNCT04785742Phase 2
• A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)Status unknownNCT04778800Not applicable
• Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsActive, not recruitingNCT04687241Phase 3
• Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung CancerActive, not recruitingNCT04685070Phase 2
• A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain MetastasesStatus unknownNCT04643847Phase 2
• A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLCStatus unknownNCT04636593Phase 2
• Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialStatus unknownNCT04553887Phase 2
• Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIsStatus unknownNCT04519983Phase 2
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Phase 3
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell CarcinomaStatus unknownNCT04354961Phase 2
• A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCStatus unknownNCT03904823Phase 2

← Aumolertinib overview